TY  - JOUR
T1  - Chemoprevention for keratinocytic (pre)cancers: Balancing the risks and benefits
AU  - Hollestein LM, Koomen ER, Nijsten T
Y1  - 2012/05/01
N1  - 10.1001/archdermatol.2011.2273
JO  - Archives of Dermatology
SP  - 638
EP  - 640
VL  - 148
IS  - 5
N2  - 
Setting: Eight centers in the United States participated and included 240 patients from January 2001 to November 2006, when the Food and Drug Administration requested termination of this trial after the worldwide withdrawal of rofecoxib.

SN  - 0003-987X
M3  - doi: 10.1001/archdermatol.2011.2273
UR  - http://dx.doi.org/10.1001/archdermatol.2011.2273
ER  -